China Eastern Orders 25 Airbus A330neo Jets in $9.35 Billion Deal to Boost International Expansion 
SK Hynix Targets $29.4 Billion Nasdaq Listing to Expand AI Chip Business 
SpaceX Stock Rebounds After Sharp Selloff, But Valuation Concerns Persist 
Fortescue Faces Class Action Over Sexual Harassment Claims at Australian Mining Sites 
SpaceX, Charter Communications Explore Mobile Partnership to Expand Starlink Wireless Service 
Italy Investigates Microsoft Over Microsoft 365 AI Subscription Price Hike 
Samsung and SK Hynix Shares Jump After Micron Earnings Boost AI Chip Optimism 
Kioxia Targets U.S. Listing as AI Chip Boom Accelerates 
Trump Orders DOJ Investigation Into Exxon, Chevron Over High Gas Prices 
Cerebras Revenue Forecast Tops Expectations, but Margin Concerns Weigh on Stock 
Alibaba Shares Fall After Anthropic Alleges Massive AI Model Distillation Campaign 
Doncasters Raises $919 Million in NYSE IPO as Aerospace Growth Accelerates 
OpenAI May Delay IPO to 2027 Amid $1 Trillion Valuation Goal 
Apple Supplier Stocks Slide as Samsung, SK Hynix Lead Selloff After Apple Price Hikes 
Micron Stock Surges on Strong AI Demand, Record Revenue, and Bullish Q4 Forecast 
US Judge Seeks Explanation for DOJ’s Decision to Drop Gautam Adani Bribery Case 
Bayer Wins Major U.S. Supreme Court Roundup Lawsuit, Shares Surge 
With the world impacted by the pandemic, the goal to bring medical alternatives to market first is now the utmost priority for many pharmaceutical companies. In support of finding these solutions, Samsung Biologics has signed a contract manufacturing agreement with GlaxoSmithKline (GSK) to produce neutralizing antibodies for COVID-19.
In April, GSK invested $250 million in the research of Vir Biotechnology to create a collaborative COVID-19 antibody treatment. With no approved treatment currently on the market, the collaborative efforts are looking at antibodies of recovered patients to see how they can help new patients recover. This is different than plasma therapy with antibodies because Vir is selecting key antibodies from the plasma to establish a process easier to administer on a large scale, making it more efficient to reach a global market. Samsung Biologics looks to help speed up that solution by offering its manufacturing service to GSK
The boost of outsourcing contracts that Samsung Biologics has gained during the COVID-19 pandemic can be largely chalked up to their unwavering drive towards quality and innovation. The company prides itself on offering a wide range of services, so clients need fewer jumps in their production and testing process.
Samsung Biologics also recently announced plans for a fourth plant expansion—estimated to invest around 2 billion USD—which will maximize operational efficiency, scale up its development and manufacturing capabilities, and through a second bio complex, foster biotech companies with an Open Innovation Center and global R&D facility.
In a time where resilient supply chains and pharmaceutical solutions are desperately needed, Samsung Biologics is filling the gap. Clients can use the large capacity and proven regulatory track record to place their products in good hands for a faster-to-market turnaround. The company also works to cut excess production time and create a development process that works best for the client. The goal is to get quality products into the hands of the patients that desperately need them.
This article does not necessarily reflect the opinions of the editors or management of EconoTimes
